PB 1046

Drug Profile

PB 1046

Alternative Names: PB-1046; Vasomera

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Antihypertensives; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Pulmonary arterial hypertension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiomyopathies; Heart failure
  • Preclinical Cystic fibrosis; Pulmonary hypertension
  • No development reported Essential hypertension

Most Recent Events

  • 18 Jan 2017 PhaseBio Pharmaceuticals plans a phase II trial for Pulmonary hypertension in the first half of 2017
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Essential-hypertension in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Essential-hypertension in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top